Results from the Clinical Trial of Qilu Pharmaceutical’s Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting

By / 04/03/2024

The European Society of Gynecological Oncology 2024 Conference has recently made selected abstracts available online.